(0.35%) 5 117.83 points
(0.34%) 38 368 points
(0.38%) 15 989 points
(-0.95%) $83.05
(5.51%) $2.03
(0.33%) $2 355.00
(0.44%) $27.66
(4.09%) $959.80
(-0.26%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
@ $17.41
発行日: 15 2月 2024 @ 04:15
リターン: -14.07%
前回のシグナル: 2月 15 - 03:13
前回のシグナル:
リターン: 1.58 %
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
本日の出来高 | 122 803 |
平均出来高 | 1.56M |
時価総額 | 927.96M |
EPS | $0 ( 2024-03-20 ) |
次の収益日 | ( $-0.640 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.47 |
ATR14 | $0.0310 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Employee stock option (right to buy) |
2024-04-04 | Peters Jeffrey Stuart | Buy | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 147 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 232 | Common Stock |
INSIDER POWER |
---|
43.90 |
Last 100 transactions |
Buy: 2 053 694 | Sell: 721 474 |
ボリューム 相関
MacroGenics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
MacroGenics Inc 相関 - 通貨/商品
MacroGenics Inc 財務諸表
Annual | 2023 |
収益: | $58.75M |
総利益: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2023 |
収益: | $58.75M |
総利益: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2022 |
収益: | $151.94M |
総利益: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
収益: | $75.64M |
総利益: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。